LSD, commonly called acid, occupies an unusual place in pharmacology: it is one of the most potent psychoactive substances known by weight, yet it carries a physical safety profile that ranks well below alcohol, opioids, and stimulants in harm-assessment studies. The genuine pros include a growing body of clinical evidence for treating depression, anxiety, and addiction, along with lasting changes in personality traits like openness. The genuine cons include the risk of deeply distressing psychological experiences, a small but real chance of triggering prolonged psychotic episodes in vulnerable people, and a poorly understood condition in which visual disturbances persist long after the drug has left the body. What makes the topic interesting is that many of these pros and cons are entangled with each other, and the same mechanisms that produce therapeutic benefit can, in the wrong circumstances, produce harm.
Therapeutic Evidence for Depression and Anxiety
The most compelling “pro” case for LSD comes from clinical research on mood and anxiety disorders. A systematic review covering 25 years of clinical trials found that LSD, along with psilocybin and ayahuasca, showed beneficial effects for treatment-resistant depression, anxiety and depression linked to life-threatening illness, and tobacco and alcohol dependence.1PubMed Central. Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years The emphasis on “treatment-resistant” matters here. These are patients for whom standard antidepressants have already failed, a population that conventional psychiatry struggles with.
More recent work has tested this further. A randomized trial comparing low-dose and high-dose LSD-assisted therapy in patients with major depression found that the high-dose group showed meaningfully larger reductions in depression scores, though the results narrowly missed statistical significance on one of the primary measures after adjusting for baseline severity. The researchers described the findings as supporting further investigation in a larger trial.2PubMed. Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial That is an honest characterization: promising, but not yet definitive.
The anxiety research is somewhat further along. In a study of people with anxiety related to life-threatening illness, participants who received LSD-assisted psychotherapy reported reductions in anxiety that persisted for at least 12 months. About three-quarters of participants described a meaningful drop in anxiety, and roughly two-thirds reported improved quality of life.3PubMed. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects A separate open-label follow-up study confirmed that anxiety, depression, and general psychiatric symptoms remained reduced up to 12 months after the final session.4PubMed Central. LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up These are small studies, and the absence of large-scale phase 3 trials is the main caveat. But the durability of the effect is striking, especially compared with conventional anxiolytics that typically require daily dosing.
Addiction Treatment
One of the earliest clinical uses of LSD was in treating addiction, and this line of research has a surprisingly long history. A controlled study with chronic heroin users found that verified abstinence rates over the first year after treatment were significantly better in the LSD-assisted therapy group than in the control group.5Archives of General Psychiatry. Residential Psychedelic (LSD) Therapy for the Narcotic Addict: A Controlled Study Similar early work on alcohol dependence produced enough positive signal that researchers in the 1950s and 1960s considered LSD-assisted therapy a genuinely viable approach to alcoholism.
That early research was disrupted when the manufacturer Sandoz stopped providing LSD for clinical use in 1965, and when nonmedical use was prohibited in 1970.6PubMed. Why was early therapeutic research on psychedelic drugs abandoned? Decades of prohibition effectively froze the science in place. The modern revival has leaned more heavily on psilocybin for addiction research, but the earlier LSD findings remain part of the evidence base and are consistent with the broader systematic review conclusions about psychedelics and substance dependence.7PubMed Central. Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years
What LSD Does to the Brain
Understanding the mechanism helps explain both the therapeutic potential and the risks. LSD acts primarily at serotonin receptors, especially the 5-HT2A subtype, and its most measurable effect on brain imaging is a dramatic increase in connectivity between regions that do not normally communicate much. Neuroimaging research has shown that under LSD, high-level association cortices, including areas overlapping with the default-mode, salience, and frontoparietal attention networks, along with the thalamus, show increased global connectivity. LSD also inflates communication between normally distinct brain networks.8Current Biology. LSD aumenta la conectividad funcional global de regiones corticales y subcorticales integradoras de nivel superior
In plain terms, LSD loosens the usual boundaries between brain networks. This is likely why the experience involves synesthesia-like blending of senses, dissolving of the sense of self (“ego dissolution”), and the feeling that habitual thought patterns have been shaken loose. It also creates an increase in brain entropy, a measure of how unpredictable neural activity becomes. Those entropy increases during the acute experience predicted lasting increases in the personality trait of openness weeks later, and the effect was strongest when people reported ego dissolution.9PubMed Central. LSD-induced entropic brain activity predicts subsequent personality change
At the cellular level, psychedelics including LSD promote structural changes in neurons: the growth of new dendrites and dendritic spines, which are the physical substrates of brain connections. This process depends on the BDNF/TrkB signaling pathway; when that pathway was experimentally blocked, psychedelics lost their ability to stimulate neuron growth.10Cell Reports. Psychedelics Promote Structural and Functional Neural Plasticity This neuroplasticity mechanism is thought to underlie the lasting therapeutic effects. Depression and chronic anxiety are associated with reduced connectivity in certain brain circuits, and psychedelics may help “rewire” those circuits during the acute experience and the period that follows.
Psychological Risks
The same loosening of brain network boundaries that creates therapeutic potential also creates the possibility of acutely terrifying experiences. “Bad trips” involve overwhelming anxiety, paranoia, confusion, and sometimes psychotic-like symptoms during the acute experience. LSD’s potential to cause psychological disturbance has been understood since the beginning of its clinical use, and the disturbance has, in rare cases, been linked to accidental deaths and suicide.11PubMed. Is LSD toxic?
The more serious concern is whether LSD can trigger lasting psychosis. A meta-analysis pooling data from nearly 8,000 participants found an overall incidence of psychedelic-induced psychosis of about 0.4%. In healthy participants without preexisting psychiatric conditions, that figure dropped to about 0.2%. In patients with schizophrenia, however, the incidence was considerably higher at roughly 4%, though those studies were conducted decades ago and in almost all cases the psychotic symptoms did not persist long-term.12Molecular Psychiatry. Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies Earlier clinical literature described “LSD psychosis” as essentially a drug-triggered schizophreniform reaction in people who were already vulnerable to both substance abuse and psychosis.13PubMed. LSD psychosis or LSD-induced schizophrenia? A multimethod inquiry
The practical takeaway is that risk of lasting psychosis is very low in the general population but meaningful for people with a personal or family history of psychotic disorders. This is why virtually all modern clinical trials screen out participants with such histories. If you have a first-degree relative with schizophrenia or bipolar disorder with psychotic features, the risk calculus changes substantially.
Hallucinogen Persisting Perception Disorder
A distinct and often poorly understood risk is hallucinogen persisting perception disorder, or HPPD. People with HPPD continue to experience visual disturbances, including trailing images, halos, geometric patterns, and visual snow, long after the drug has worn off. The condition can last months or years and cause significant distress. LSD is the substance most commonly associated with HPPD in the clinical literature.14PubMed Central. Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives15PubMed Central. Hallucinogen-Induced Persisting Perception Disorder: A Case Report
HPPD appears to be genuine but uncommon, and it is reported more frequently after illicit LSD use than after LSD administered in research or clinical settings.16Drug and Alcohol Dependence. Hallucinogen persisting perception disorder: what do we know after 50 years? That distinction matters. The difference may relate to dose, frequency of use, set and setting, or some combination. Exact prevalence figures are hard to pin down because most data come from case reports and retrospective surveys, not prospective tracking. The mechanism is not well understood, and no widely accepted treatment exists, making HPPD one of the more frustrating unknowns in psychedelic pharmacology.
Physical Safety and Cardiovascular Effects
Compared with many recreational drugs, LSD has an unusual physical safety profile. Controlled studies in healthy adults show that it significantly increases blood pressure, heart rate, body temperature, pupil size, and stress hormones like cortisol and epinephrine.17PubMed. Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects A head-to-head comparison with psilocybin found that LSD produced a greater increase in heart rate than psilocybin at equivalent subjective doses, though both substances raised blood pressure and body temperature only moderately.18Neuropsychopharmacology. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects
These cardiovascular effects are transient and generally well tolerated in healthy young adults. But they are worth knowing about if you have a preexisting heart condition or uncontrolled high blood pressure. A review specifically examining LSD and the heart confirmed that acute ingestion causes tachycardia and hypertension, consistent with other psychedelics.19PubMed Central. Lysergic Acid Diethylamide (LSD) and the Heart: Exploring the Potential Impacts of LSD on Cardiovascular Function No confirmed lethal dose of LSD has been established in humans from controlled data, and fatal overdoses in the medical literature are extraordinarily rare. The drug’s physical danger lies more in the impaired judgment and risky behavior it can facilitate than in direct organ toxicity.
How LSD Compares to Other Substances in Harm Rankings
Multi-criteria harm-ranking studies, which weigh both harm to the user and harm to others across categories like mortality, dependence, injury, and social damage, consistently place LSD near the bottom of the list. A New Zealand drug-harms analysis ranked alcohol as the most harmful drug overall, followed by methamphetamine and synthetic cannabinoids. All opioid categories clustered together in the upper-middle range.20PubMed Central. The New Zealand drug harms ranking study: A multi-criteria decision analysis LSD and psilocybin consistently score among the lowest-harm substances in these analyses, largely because they are not associated with dependence, carry low organ toxicity, and cause very little harm to third parties. These rankings do not mean LSD is safe in every context; they mean the aggregate population-level harm is low relative to legal substances like alcohol.
The Microdosing Question
Microdosing, taking roughly one-tenth to one-twentieth of a full dose every few days, has attracted enormous popular interest. The claimed benefits include improved mood, sharper focus, and enhanced creativity. The controlled evidence is mixed and considerably less exciting than the anecdotes.
A placebo-controlled dose-response study in healthy volunteers found that low LSD doses (5, 10, and 20 micrograms) had some positive effects on mood and reduced attentional lapses, but also increased confusion and anxiety at the 20-microgram level.21PubMed. Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study A separate placebo-controlled study using repeated low doses of 26 micrograms found that the drug produced some subjective sense of “feeling a drug effect” and stimulant-like qualities, but did not improve mood or performance on most emotional and psychomotor tasks. No lasting changes in mood or cognition were detected at follow-up.22PubMed Central. Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study
A rapid review of the broader microdosing literature found a consistent acute increase in feelings of vigor and some indications of improved positive mood on dosing days, but little evidence that these changes persisted over weeks of microdosing. Several studies failed to find any effect of microdosing on standard cognitive batteries, creativity tasks, or suggestibility.23PubMed Central. Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research The honest summary: microdosing produces subtle acute effects on mood in some people, but the evidence for lasting cognitive or emotional benefits in healthy people is thin. The gap between what microdosing enthusiasts report and what controlled studies find is wide enough to make expectancy effects (placebo) a plausible explanation for much of the popular experience.
Why Set and Setting Matter So Much
One of the things that makes evaluating LSD’s pros and cons harder than evaluating, say, a blood pressure medication is that the outcome of an LSD experience depends heavily on context. “Set” refers to the person’s mindset going in, including their expectations, emotional state, and motivations. “Setting” refers to the physical and social environment. A study examining how these factors predict outcomes found that growth-oriented motivations, natural settings, and the presence of trusted companions predicted less psychopathology, greater well-being, and more meaningful experiences. Problematic motivations, like using the drug to escape distress, predicted more psychopathology and lower well-being.24PubMed. Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study
This is why clinical trials pair the drug with trained therapists, comfortable rooms, and careful psychological preparation. It is also why recreational use in chaotic or unfamiliar environments carries a higher risk of distressing experiences. The same molecule, in different contexts, can produce vastly different outcomes, which means that blanket statements about LSD being “good” or “bad” miss the point. The question is always: for whom, in what dose, in what setting, and with what support?
Interactions with Antidepressants
If you are currently taking an antidepressant that affects serotonin, the interaction with LSD is worth understanding. A survey of people who had taken LSD while on serotonin reuptake inhibitors found that about 88% of those who had been on the antidepressant for more than three weeks experienced a subjective decrease or virtual elimination of their response to LSD.25Neuropsychopharmacology. Chronic Administration of Serotonergic Antidepressants Attenuates the Subjective Effects of LSD in Humans A larger prospective survey study confirmed this pattern: people not taking serotonin reuptake inhibitors reported significantly more intense subjective effects, including stronger mystical experiences, more challenging experiences, and more emotional breakthroughs.26PubMed Central. Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study
This has practical implications in two directions. First, people on SSRIs who try LSD recreationally may find it does almost nothing, which sometimes leads them to take a dangerously large dose in an attempt to compensate. Second, the clinical trial protocols that are producing the positive therapeutic results described earlier typically require participants to taper off antidepressants before receiving LSD, which introduces its own medical risks. This interaction complicates the path from promising trial results to real-world psychiatric use, because many of the patients who could benefit most are already on serotonergic medications.
Who Should Avoid LSD Entirely
Several groups face disproportionate risk. People with a personal or strong family history of psychotic disorders, particularly schizophrenia, carry a meaningfully higher chance of a drug-induced psychotic episode, as the meta-analysis data on psychosis incidence showed. People with severe cardiovascular conditions should be cautious given the acute increases in blood pressure and heart rate. Pregnant individuals lack safety data entirely. And anyone in an unstable emotional state or unfamiliar, unsupervised environment faces elevated odds of a psychologically harmful experience, per the set-and-setting research.
Adolescents and young adults whose brains are still developing represent another concern. Most clinical trials enroll adults over 18 or 25, and no controlled data exist on the effects of LSD on the developing brain. The neuroplasticity-promoting properties that make LSD therapeutically interesting in adults could theoretically be disruptive during a developmental period when the brain is already undergoing rapid structural change, though this remains speculative rather than demonstrated.
The Gap Between Research Settings and Real-World Use
Nearly all the positive therapeutic data come from controlled clinical environments: screened participants, pharmaceutical-grade LSD at known doses, trained therapists, comfortable rooms, integration sessions afterward. The real-world situation is different in every one of those dimensions. Street LSD comes in unknown doses, sometimes on blotter paper containing other substances entirely. There is no pre-screening for psychiatric vulnerability, no trained guide, and often no safe physical environment. The evidence for HPPD being more common after illicit use than clinical use hints at how much context matters.27Drug and Alcohol Dependence. Hallucinogen persisting perception disorder: what do we know after 50 years?
This gap means you should be cautious about mapping clinical trial results onto recreational or self-therapeutic use. The trials are not showing that LSD is beneficial; they are showing that LSD-assisted therapy, conducted with preparation, dosing precision, and professional support, appears beneficial. Strip away those supports and you keep the molecule’s potency while losing most of the safeguards that made the clinical outcomes positive. The distinction between the drug and the protocol built around it is easy to blur but critical to understand.